Cargando…

Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance

BACKGROUND: There is recent evidence suggesting that rosiglitazone increases death from cardiovascular causes. We investigated the direct effect of this drug on atheroma using 3D carotid cardiovascular magnetic resonance. RESULTS: A randomized, placebo-controlled, double-blind study was performed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Varghese, Anitha, Yee, Michael S, Chan, Cheuk F, Crowe, Lindsey A, Keenan, Niall G, Johnston, Desmond G, Pennell, Dudley J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726137/
https://www.ncbi.nlm.nih.gov/pubmed/19635160
http://dx.doi.org/10.1186/1532-429X-11-24
_version_ 1782170570472816640
author Varghese, Anitha
Yee, Michael S
Chan, Cheuk F
Crowe, Lindsey A
Keenan, Niall G
Johnston, Desmond G
Pennell, Dudley J
author_facet Varghese, Anitha
Yee, Michael S
Chan, Cheuk F
Crowe, Lindsey A
Keenan, Niall G
Johnston, Desmond G
Pennell, Dudley J
author_sort Varghese, Anitha
collection PubMed
description BACKGROUND: There is recent evidence suggesting that rosiglitazone increases death from cardiovascular causes. We investigated the direct effect of this drug on atheroma using 3D carotid cardiovascular magnetic resonance. RESULTS: A randomized, placebo-controlled, double-blind study was performed to evaluate the effect of rosiglitazone treatment on carotid atherosclerosis in subjects with type 2 diabetes and coexisting vascular disease or hypertension. The primary endpoint of the study was the change from baseline to 52 weeks of carotid arterial wall volume, reflecting plaque burden, as measured by carotid cardiovascular magnetic resonance. Rosiglitazone or placebo was allocated to 28 and 29 patients respectively. Patients were managed to have equivalent glycemic control over the study period, but in fact the rosiglitazone group lowered their HbA1c by 0.88% relative to placebo (P < 0.001). Most patients received a statin or fibrate as lipid control medication (rosiglitazone 78%, controls 83%). Data are presented as mean ± SD. At baseline, the carotid arterial wall volume in the placebo group was 1146 ± 550 mm(3 )and in the rosiglitazone group was 1354 ± 532 mm(3). After 52 weeks, the respective volumes were 1134 ± 523 mm(3 )and 1348 ± 531 mm(3). These changes (-12.1 mm(3 )and -5.7 mm(3 )in the placebo and rosiglitazone groups, respectively) were not statistically significant between groups (P = 0.57). CONCLUSION: Treatment with rosiglitazone over 1 year had no effect on progression of carotid atheroma in patients with type 2 diabetes mellitus compared to placebo.
format Text
id pubmed-2726137
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27261372009-08-13 Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance Varghese, Anitha Yee, Michael S Chan, Cheuk F Crowe, Lindsey A Keenan, Niall G Johnston, Desmond G Pennell, Dudley J J Cardiovasc Magn Reson Research BACKGROUND: There is recent evidence suggesting that rosiglitazone increases death from cardiovascular causes. We investigated the direct effect of this drug on atheroma using 3D carotid cardiovascular magnetic resonance. RESULTS: A randomized, placebo-controlled, double-blind study was performed to evaluate the effect of rosiglitazone treatment on carotid atherosclerosis in subjects with type 2 diabetes and coexisting vascular disease or hypertension. The primary endpoint of the study was the change from baseline to 52 weeks of carotid arterial wall volume, reflecting plaque burden, as measured by carotid cardiovascular magnetic resonance. Rosiglitazone or placebo was allocated to 28 and 29 patients respectively. Patients were managed to have equivalent glycemic control over the study period, but in fact the rosiglitazone group lowered their HbA1c by 0.88% relative to placebo (P < 0.001). Most patients received a statin or fibrate as lipid control medication (rosiglitazone 78%, controls 83%). Data are presented as mean ± SD. At baseline, the carotid arterial wall volume in the placebo group was 1146 ± 550 mm(3 )and in the rosiglitazone group was 1354 ± 532 mm(3). After 52 weeks, the respective volumes were 1134 ± 523 mm(3 )and 1348 ± 531 mm(3). These changes (-12.1 mm(3 )and -5.7 mm(3 )in the placebo and rosiglitazone groups, respectively) were not statistically significant between groups (P = 0.57). CONCLUSION: Treatment with rosiglitazone over 1 year had no effect on progression of carotid atheroma in patients with type 2 diabetes mellitus compared to placebo. BioMed Central 2009-07-27 /pmc/articles/PMC2726137/ /pubmed/19635160 http://dx.doi.org/10.1186/1532-429X-11-24 Text en Copyright © 2009 Varghese et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Varghese, Anitha
Yee, Michael S
Chan, Cheuk F
Crowe, Lindsey A
Keenan, Niall G
Johnston, Desmond G
Pennell, Dudley J
Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance
title Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance
title_full Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance
title_fullStr Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance
title_full_unstemmed Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance
title_short Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance
title_sort effect of rosiglitazone on progression of atherosclerosis: insights using 3d carotid cardiovascular magnetic resonance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726137/
https://www.ncbi.nlm.nih.gov/pubmed/19635160
http://dx.doi.org/10.1186/1532-429X-11-24
work_keys_str_mv AT vargheseanitha effectofrosiglitazoneonprogressionofatherosclerosisinsightsusing3dcarotidcardiovascularmagneticresonance
AT yeemichaels effectofrosiglitazoneonprogressionofatherosclerosisinsightsusing3dcarotidcardiovascularmagneticresonance
AT chancheukf effectofrosiglitazoneonprogressionofatherosclerosisinsightsusing3dcarotidcardiovascularmagneticresonance
AT crowelindseya effectofrosiglitazoneonprogressionofatherosclerosisinsightsusing3dcarotidcardiovascularmagneticresonance
AT keenanniallg effectofrosiglitazoneonprogressionofatherosclerosisinsightsusing3dcarotidcardiovascularmagneticresonance
AT johnstondesmondg effectofrosiglitazoneonprogressionofatherosclerosisinsightsusing3dcarotidcardiovascularmagneticresonance
AT pennelldudleyj effectofrosiglitazoneonprogressionofatherosclerosisinsightsusing3dcarotidcardiovascularmagneticresonance